Spyre Therapeutics’ SPY001 shows efficacy in two poster presentations

Spyre Therapeutics (SYRE) announced two poster presentations at Digestive Disease Week 2025 in San Diego. Spyre presented results out to eight months of follow up from its SPY001 Phase 1 program. Updated results from the ongoing Phase 1 trial of SPY001, its novel half-life extended alpha4beta7 antibody for the treatment of IBD, continues to show that SPY001 is well tolerated, has a half-life of more than three-fold compared to vedolizumab based on population PK modeling, and sustains target engagement at expected Phase 2 trough concentrations. This longer follow-up data strengthens the potential for SPY001 to demonstrate improved induction responses with greater exposures as well as durable responses with quarterly or biannual maintenance dosing. Spyre presented expanded preclinical data on combined inhibition of alpha4beta7 integrin and TL1A cytokine in murine colitis models. Data presented demonstrate that combined inhibition of alpha4beta7 integrin and TL1A cytokine is superior to either monotherapy in mouse models of colitis.